Market revenue in 2023 | USD 415.4 million |
Market revenue in 2030 | USD 1,084.1 million |
Growth rate | 14.7% (CAGR from 2023 to 2030) |
Largest segment | Reagents & kits |
Fastest growing segment | Reagents & kits |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Instruments, Reagents & kits, Services |
Key market players worldwide | Illumina Inc, Thermo Fisher Scientific Inc, Qiagen NV, Roche, Fluidigm Corporation, Danaher Corp, Agilent Technologies, Eurofins Scientific SE, GE HealthCare Technologies Inc Common Stock, Bio-Rad Laboratories Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to genotyping market will help companies and investors design strategic landscapes.
Reagents & kits was the largest segment with a revenue share of 61.17% in 2023. Horizon Databook has segmented the Spain genotyping market based on instruments, reagents & kits, services covering the revenue growth of each sub-segment from 2018 to 2030.
Genomic diagnostic instruments and service providers are developing novel technologies with improved accuracy, speed, and sensitivity. Such advanced diagnostic solutions are essential part of genetic-based diagnosis. Commonly performed diagnostic tests in the country include HPV testing for cervical cancer, diagnosis of viral load, and detection of genetic region linked to disorders such as cancer.
Strategic initiatives being undertaken by local players are anticipated to drive market growth. Genomica S.A.U is one of the key companies in Spain, which actively provides genotyping solutions related to diagnostics such as the Clart HPV line, an IVD diagnostic product for genotyping & detection of various HPV.
This technology uses multiplex PCR and low-density arrays. Similarly, Roche also provides a genotyping-based HPV diagnostic solution through its cobas 4800 system. Presence of all these players with strong foothold in the market is expected to boost market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain genotyping market , including forecasts for subscribers. This country databook contains high-level insights into Spain genotyping market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account